Share

July 2018; 5 (4) ArticleOpen Access

Molecular signature of Epstein-Barr virus infection in MS brain lesions

Monica A. Moreno, Noga Or-Geva, Blake T. Aftab, Rajiv Khanna, Ed Croze, Lawrence Steinman, May H. Han
First published June 7, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000466
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1265

Share

Article Information

vol. 5 no. 4 e466
DOI: 
https://doi.org/10.1212/NXI.0000000000000466
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received December 21, 2017
  • Accepted in final form April 25, 2018
  • First Published June 7, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Monica A. Moreno, PhD,
    2. Noga Or-Geva, PhD,
    3. Blake T. Aftab, PhD,
    4. Rajiv Khanna, PhD,
    5. Ed Croze, PhD,
    6. Lawrence Steinman, MD and
    7. May H. Han, MD
  1. Monica A. Moreno, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Atara Biotherapeutics, Inc. 4360 Park Terrace Drive, Suite 100 Westlake Village, CA 91361 office: (805) 330-6526 mobile: (805) 637-4006

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Atara Biotherapeutics, Inc. 4360 Park Terrace Drive, Suite 100 Westlake Village, CA 91361 office: (805) 330-6526 mobile: (805) 637-4006

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. First author, Monica Moreno, was funded by NIH T32 (AI07290-30) during the time of the study. This publication was not related to the project funded by Dr. Moreno's NIH T32.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Noga Or-Geva, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Use of anti-third party cells for treatment of a variety of diseases including cancer and autoimmune disease or as protectors of genetically-engineered cell therapy. Patent EP2613801A2 Patent WO2017009853A1 Patent WO2017009852A1 Patent EP2613801B1 Patent CA2810632A1

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Blake T. Aftab, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Atara Biotherapeutics, Inc., Senior Director Preclinical and Translation Science, 3 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Atara Biotherapeutics, Inc.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. (1) Atara Biotherapeutics, Inc. Stock/Stock Options, Medical Equipment & Materials: (1) Atara Biotherapeutics, Inc.

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Rajiv Khanna, PhD,
    5. Scientific Advisory Boards:

    1. I am appointed on the scientific advisory board of Atara Biotherapeutics

    Gifts:

    1. I am appointed as a consultant for Atara Biotherapeutics

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I am appointed as Editor-in-chief of Clinical & Translational Immunology Journal

    Patents:

    1. I am listed as inventor on multiple international patents or patent applications which includes T cell epitopes and also immunotherapy for virus-associated diseases including manlignancies and autoimmune diseases

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I am appointed as a consultant for Atara Biotherapeutics

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I receive research and development funding from Atara Biotherapeutics.

    Research Support, Government Entities:

    1. I am currently recipient of multiple research grants from National Health and Medical Research Council (Australia).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. I have stock options from Atara Biotherapeutics.

    License fee payments, Technology or Inventions:

    1. I have received licensing payments as an inventor from Atara Biotherapeutics

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Ed Croze, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I am a consultant for Atara. Iris-Bay is my consultancy company

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Lawrence Steinman, MD and
    7. Scientific Advisory Boards:

    1. Novartis, Receptos, Atreca, Tolerion, Teva, AbbVie

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Celgene, AbbVie

    Editorial Boards:

    1. MS Journal, Proceedings National Academy of Sciences

    Patents:

    1. I have a patent pending on cytokines and type 1 interferons. I have multiple patents on antigen specific tolerance.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Atara, Celgene, Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Stock options and board membership in Tolerion Board of Directors BioAtla

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. May H. Han, MD
    8. Scientific Advisory Boards:

    1. Novartis Inc, advisory committee (1)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. University of California, San Diego (1) CMSC (1)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Sanofi-Genzyme (1)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Chartiable Foundation for NMO Research (1) Fondation Leducq (2)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology and Neurological Sciences (M.A.M., N.O., L.S., M.H.H.), Stanford University School of Medicine, Multiple Sclerosis Center; Interdepartmental Program in Immunology (M.A.M., N.O., L.S., M.H.H.), Stanford; Atara Biotherapeutics (B.T.A., E.C.), San Francisco, CA; and Queensland Institute of Medical Research (R.K.), Brisbane, Queensland, Australia.
  1. Correspondence
    Dr. Han mayhan{at}stanford.edu
View Full Text

Article usage

Article usage: June 2018 to May 2019

AbstractFullPdfSource
Jun 201802083395Highwire
Jun 2018367280pmc
Jul 201802574163Highwire
Aug 20181763101Highwire
Aug 2018307381pmc
Sep 20181595102Highwire
Oct 2018044352Highwire
Nov 2018029180Highwire
Dec 2018037034Highwire
Jan 2019529632Highwire
Feb 2019624040Highwire
Mar 2019220740Highwire
Apr 2019221830Highwire
May 2019719135Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement